Recent advances in hyaline membrane disease.
Survival of infants with HMD has improved remarkably in the last decade. This has resulted from improved methods of diagnosis, which enables clinicians to recognize infection, the patent ductus, and the presence of pulmonary hypertension complicating HMD; from improved methods of ventilation, which result in a lower incidence of acute and chronic complications; and from a reduced incidence of pulmonary and extrapulmonary complications, such as bronchopulmonary dysplasia and retrolental fibroplasia. These advances arise from a deep understanding of pulmonary and metabolic physiology of the newborn infant with respiratory distress. Only an approach firmly rooted in an understanding of physiology, pharmacology, and biochemistry can be completely successful in the therapy of these infants.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004374:Ductus Arteriosus, Patent / Q000628:therapy; D006801:Humans; D006819:Hyaline Membrane Disease / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*; D007231:Infant, Newborn; D012121:Respiration, Artificial; D012127:Respiratory Distress Syndrome, Newborn / Q000628:therapy
D000900:Anti-Bacterial Agents